Skip to the beginning of the images gallery

ABT-737 - ≥97%, high purity , CAS No.852808-04-9, Antagonist of BCL2 apoptosis regulator;Antagonist of Bcl-2-like 1;Antagonist of Bcl-2-like 2

Moligand™
≥97%

CAS#: 852808-04-9
Formula: C₄₂H₄₅ClN₆O₅S₂
Molecular Weight: 813.43
PubChem CID: 11228183

Item Number

A127419

Grouped product items
SKU	Size	Availability	Price
A127419-5mg	5mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$81.90
A127419-25mg	25mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$369.90
A127419-100mg	100mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$576.90

BH3 mimetic Bcl-xL, Bcl-2 and Bcl-w inhibitor

View related series

Bcl-2-like 1 Antagonist Bcl-2-like 2 Antagonist BCL2 apoptosis regulator Antagonist

Basic Description

Synonyms	ABT-737\|852808-04-9\|ABT 737\|ABT737\|UNII-Z5NFR173NV\|4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide\|Z5NFR173NV\|(R)-4-(4-((4'-chloro-[1,1'-biphen
Specifications & Purity	Moligand™, ≥97%
Biochemical and Physiological Mechanisms	ABT-737 is a pan-Bcl-2 inhibitor that has a wide range of single-agent activity against acute lymphoblastic leukemia (ALL) cell lines and xenografts. Increased expression of the Bcl-2 family of proteins in cancers has been associated with chemotherapy res
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Grade	Moligand™
Action Type	ANTAGONIST
Mechanism of action	Antagonist of BCL2 apoptosis regulator;Antagonist of Bcl-2-like 1;Antagonist of Bcl-2-like 2
Note	Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description	ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. A selective inhibitor of Bcl-2

Associated Targets

MDM2 Tchem E3 ubiquitin-protein ligase Mdm2 0 Activities

Discover Target: MDM2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

HDAC6 Tclin Histone deacetylase 6 0 Activities

Discover Target: HDAC6

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PKM Tchem Pyruvate kinase PKM 0 Activities

Discover Target: PKM

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

MCL1 Tchem Induced myeloid leukemia cell differentiation protein Mcl-1 0 Activities

Discover Target: MCL1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

CSN2 Tbio Beta-casein 0 Activities

Discover Target: CSN2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BID Tbio BH3-interacting domain death agonist 0 Activities

Discover Target: BID

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BAD Tchem Bcl2-associated agonist of cell death 1 Activities

Discover Target: BAD

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BCL2 Tclin Apoptosis regulator Bcl-2 19 Activities

Discover Target: BCL2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BCL2L1 Tchem Bcl-2-like protein 1 32 Activities

Discover Target: BCL2L1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BCL2A1 Tchem Bcl-2-related protein A1 0 Activities

Discover Target: BCL2A1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BCL2L2 Tchem Bcl-2-like protein 2 4 Activities

Discover Target: BCL2L2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

BCL2L10 Tchem Bcl-2-like protein 10 0 Activities

Discover Target: BCL2L10

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ASPH Tchem Aspartyl/asparaginyl beta-hydroxylase 0 Activities

Discover Target: ASPH

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Names and Identifiers

IUPAC Name	4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide
INCHI	InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1
InChi Key	HPLNQCPCUACXLM-PGUFJCEWSA-N
Canonical SMILES	CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]
Isomeric SMILES	CN(C)CC[C@H](CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]
PubChem CID	11228183
Molecular Weight	813.43

CAS Registry No.

PubChem CID

ChEMBL Ligand

RCSB PDB Ligand

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot Number	Certificate Type	Date	Item
L2015183	Certificate of Analysis	Oct 15, 2022	A127419
L1613030	Certificate of Analysis	Jul 19, 2022	A127419

Solubility

DMSO ≥160mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL

Refractive Index

1.7

Melt Point(°C)

148-151°C

References

1. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace Jr AJ. (2000) An informatics approach identifying markers of chemosensitivity in human cancer cell lines.. Cancer Res, 60 (21): (6101-10). [PMID:11085534]
2. Green DR, Evan GI. (2002) A matter of life and death.. Cancer Cell, 1 (1): (19-30). [PMID:12086884]
3. Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A. (2007) The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.. Clin Cancer Res, 13 (23): (7191-8). [PMID:18056200]
4. Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC et al.. (2007) Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.. J Med Chem, 50 (4): (641-62). [PMID:17256834]
5. Jain HV, Meyer-Hermann M. (2011) The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.. Cancer Res, 71 (3): (705-15). [PMID:21169413]
6. Tian BP, Xia LX, Bao ZQ, Zhang H, Xu ZW, Mao YY, Cao C, Che LQ, Liu JK, Li W et al.. (2017) Bcl-2 inhibitors reduce steroid-insensitive airway inflammation.. J Allergy Clin Immunol, 140 (2): (418-430). [PMID:28043871]
7. Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A et al.. (2015) Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.. Int J Cancer, 136 (5): (E340-50). [PMID:25066666]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.